



70-year-old man with a 2-month
history of painless jaundice,
pruritis, and scleral icterus

Kaitlyn Petitpas, MS3


CT with Oral Contrast




CT with Oral Contrast




CT with Oral Contrast



CT with Oral Contrast



CT with Oral Contrast






?

Metastatic Pancreatic Adenocarcinoma

CT with Oral Contrast


Precarinal
lymphadenopathy



Subpleural nodules


Right upper lobe nodule

CT with Oral Contrast



Subpleural
nodule

CT with Oral Contrast



Subtle ill-defined
hypodense liver lesion




Ascites

CT with Oral Contrast



Biliary stents; no intrahepatic
biliary duct dilatation



Hypodense mass in
the pancreatic head

Pancreatic Adenocarcinoma

Malignancy arising from ductal epithelium of the exocrine pancreas

- Most common malignant tumor of exocrine pancreas
- Accounts for >95% of pancreatic malignancies
- 60% in pancreatic head, 20% in body, 15% are diffuse, 5% in tail
- Often asymptomatic early in disease course resulting in late presentation
- Most common symptoms are jaundice, weight loss, abdominal pain, back pain
- Poor prognosis
 - Only potentially curative treatment is complete surgical resection with negative surgical margins
 - Only 15-20% of patients are surgical candidates at presentation; 5-year survival after surgery is 20%
 - Without surgery, 5-year survival is < 5%; median survival of 3.5 months
- CT
 - 97% sensitivity for detecting pancreatic cancer
 - Excellent in determining unresectability
 - Less effective in determining resectability as many tumors found to be “resectable” on CT are actually unresectable at surgery
 - Best modality for determining vascular invasion

Imaging Findings

Ultrasound

- Hypoechoic mass with minimal internal color doppler flow vascularity
- Biliary dilation and pancreatic ductal dilation upstream from tumor
- Double duct sign

Endoscopic Ultrasound

- Findings similar to those seen on conventional ultrasound
- Can help guide biopsy of pancreatic mass

CT

- Poorly margined, hypodense mass often with extensive surrounding desmoplastic reaction
- 5% are isodense to normal pancreatic parenchyma , requiring attention to secondary signs of tumor
 - Pancreatic duct and CBD obstruction with abrupt ductal cutoff at the site of obstruction
 - Pancreatic parenchymal atrophy upstream from mass
 - Abnormal contour of pancreas with loss of normal fatty lobulation and texture
 - Soft tissue infiltration involving adjacent vessels and organs
- Enhance poorly compared to adjacent normal pancreatic tissue, thus appear hypoattenuating on arterial phase scans and often become isoattenuating on delayed scans

MR

- T1: hypointense
- T1C+: Slower enhancement than the normal pancreas, therefore dynamic injection with fat saturation arterial imaging is recommended
- T2 / flair: variable intensity, depends on degree of reactive desmoplastic reaction
- MRCP: double duct sign

References

Coucke EM, Akbar H, Kahloon A, et al. Biliary Obstruction. [Updated 2022 Nov 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539698/>

Fernandez-del Castillo C, Tanabe KK, Howell DA, et al. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. UpToDate. June 08, 2022. https://www-uptodate-com.online.uchc.edu/contents/clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer?search=pancreatic%20adenocarcinoma&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H31

Vareedayah AA, Alkaade S, Taylor JR. Pancreatic Adenocarcinoma [published correction appears in Mo Med. 2018 Nov-Dec;115(6):517]. Mo Med. 2018;115(3):230-235.

<https://app.statdx.com/document/pancreatic-ductal-carcinoma/e3b28958-fd46-4c1b-8697-1229cf6d0f91>